N/A=not applicable
The baseline characteristics of the patients are summarised in Table 2. Patients were on average 51.5 years old and 63.2% were males. The majority of patients enrolled in the trial were Caucasian. No significant differences were observed between groups at baseline for age or body mass index. There were also no significant differences observed between groups at baseline for time from symptom onset, time from hospital admission and with the WHO modified ordinal scale at admission.
The time to commencement of inhaled nebulised UFH ranged from a minimum of 1 hour to a maximum of 27 hours following hospital admission, with a median time of 4 hours. Most patients at the two hospitals received a range of other treatments as standard of care, including corticosteroids (dexamethasone), antibiotics (ceftriaxone and azithromycin) and anticoagulants (typically, enoxaparin sodium intravenous (IV) or subcutaneous (SC), either in prophylactic or therapeutic doses). The standard of care treatment was not different between the two arms of the trial and included
The trial was stopped when no patients had been hospitalised with COVID-19 for 60 consecutive days in either of the two sites engaged in this trial.